Myovant Sciences Funding & Investors
Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant Sciences develops relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain.
myovant.comTotal Amount Raised: $540,000,000
Myovant Sciences Funding Rounds
Post Ipo Debt
$200,000,000
Post Ipo Debt Investors
Sumitomo Dainippon Pharma Co.Post Ipo Equity
$100,000,000
Post Ipo Equity
$100,000,000
Post Ipo Debt
$40,000,000
Post Ipo Debt Investors
Hercules CapitalPost Ipo Equity
$100,000,000
Post Ipo Equity Investors
NovaQuest Capital Management
Funding info provided by Diffbot.